Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients

European Journal of Cancer

Volumn 36, Issue 6, 2000, Pages 803-809

  Dhar, S ^a   Gullbo, J ^a   Csoka, K ^a   Eriksson, E ^a   Nilsson, K ^a   Nickel, P ^b   Larsson, R ^a   Nygren, P ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cytotoxicity; In vitro; Suramin analogue; Tumour cell

Indexed keywords

8 [4' (3'' NITROBENZAMIDO)BENZAMIDO]NAPHTHALENE 1,3,6 TRISULFONATE; FCE 26644; NF 031; NF 036; NF 037; NF 067; NF 110; SURAMIN; SURAMIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROMETRY; HUMANS; SURAMIN; TUMOR CELLS, CULTURED;

EID: 0034079646     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00024-1     Document Type: Article

References (42)

1. Stein C. Suramin. a novel antineoplastic agent with multiple potential mechanisms of action Cancer Res. 53:1993;2239-2248.
2. Morty R., Troeberg L., Pike R.et al. A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin. FEBS Lett. 433:1998;251-256.
3. Scher H., Kelly W. Suramin. defining the role in the clinic Princ. Pract. Oncol. Updates. 7:1993;1-16.
4. Voogd T., Vansterkenburg E., Wilting J., Janssen L. Recent research on the biological activity of suramin. Pharmacol. Rev. 45:1993;177-203.
5. Shin R., Naomoto Y., Kamikawa Y., Tanaka N., Orita K. Effect of suramin on human esophageal cancer cells in vitro and in vivo. Scand. J. Gastroenterol. 32:1997;824-828.
6. Frommel T. Suramin is synergistic with vinblastine in human colonic tumour cell lines. effect of cell density and timing of drug delivery Anticancer Res. 17(3C):1997;2065-2071.
7. Miglietta L., Canobbio L., Granetto C., Vannozzi M., Esposito M., Boccardo F. Suramin/epidoxorubicin association in hormone-refractory prostate cancer. preliminary results of a pilot phase II study J. Cancer Res. Clin. Oncol. 123(7):1997;407-410.
8. Minniti C., Maggi M., Helman L. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 52:1992;1830-1835.
9. Kragh Larsen A. Suramin. an anticancer drug with unique biological effects Cancer Chemother. Pharmacol. 32:1993;96-98.
10. Fujiuchi S., Ohsaki Y., Kikuchi K. Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor. Oncology. 54(2):1997;134-140.
11. Gagliardi A., Kassack M., Kreimeyer A., Muller G., Nickel P., Collins D. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother. Pharmacol. 41(2):1998;117-124.
12. Zhang Y., Keng Y., Zhao Y., Wu L., Zhang Z. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 273(20):1998;12281-12287.
13. Benini S., Baldini N., Manara M.et al. Redundancy of autocrine loops in human osteosarcoma cells. Int. J. Cancer. 80:1999;581-588.
14. Bocci G., Danesi R., Benelli U.et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Chemother. Pharmacol. 43:1999;205-212.
15. Csoka K., Nygren P., Graf W., Påhlman L., Glimelius B., Larsson R. Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Int. J. Cancer. 63:1995;356-360.
16. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line. Int. J. Cancer. 17:1976;565-577.
17. Botling J., Liminga G., Larsson R., Nygren P., Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without over expression of the 170 kDa P-glycoprotein. Int. J. Cancer. 58:1994;269-274.
18. Dalton W., Durie B., Alberts D., Gerlach J., Cress A. Characterisation of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 46:1986;5125-5130.
19. Bellamy W., Dalton W., Gleason M., Grogan T., Trent J. Development and characterisation of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 51:1991;995-1002.
20. Mulcahy R., Bailey H., Gipp J. Upregulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol. 34:1994;67-71.
21. Mirski S., Gerlach J. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47:1987;2594-2598.
22. Cole S., Bhardway G., Gerlach J., Almquist K., Deelay R. A novel ATP binding cassette transporter gene overexpressed in multidrug resistant human lung tumor cells. Science. 268:1992;1650-1654.
23. Danks M., Yalowich J., Beck W. A typical multidrug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
24. Danks M., Schmidt C., Cirtain M., Suttle D., Beck W. Altered catalytic activity of and DNA cleavage by DNA topoisomeras II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
25. 2+ concentration. Biosci. Rep. 10:1990;231-237.
26. Dhar S., Nygren P., Csoka K., Botling J., Nilsson K., Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br. J. Cancer. 74:1996;888-896.
27. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer. 50:1992;177-185.
28. Csoka K., Larsson R., Tholander B., Gerdin E., Torre M., Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric cytotoxicity assay (FMCA). Gynecol. Oncol. 54:1994;163-170.
29. Nygren P., Kristensen J., Sundström C., Lönnerholm G., Kreuger A., Larsson R. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia. 6:1992;1121-1128.
30. Boyd M., Paull K. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
31. Weisenthal L.M., Dill P.L., Pearson F.C. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J. Natl. Cancer Inst. 83:1991;37-42.
32. Nygren P., Hagberg H., Glimelius B.et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay. Ann. Oncol. 5:1994;S127-S131.
33. Nygren P., Fridborg H., Csoka K.et al. Detection of tumor specific cytotoxic drug activity in vitro using fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int. J. Cancer. 56:1994;715-720.
34. Jentsch K., Hunsmann G., Hartmann H., Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J. Gen. Virol. 68:1987;2183-2192.
35. Braddock P., Hu D., Fan T.-P., Stratford I., Harris A., Bicknell R. A structure-activity analysis of antagonism of the growth factor by suramin and related polyanions. Br. J. Cancer. 69:1994;890-898.
36. Firsching A., Nickel P., Mora P., Allolio B. Antiproliferative and angiostatic activity of suramin analogues. Cancer Res. 55:1995;4957-4961.
37. Ciomei M., Pastori W., Mariani M., Sola F., Grandi M., Mongelli N. New sulfonated distamycin A derivatives with bFGF complex activity. Biochem. Biopharmacol. 47(2):1994;295-302.
38. Vischer T.L. Suramin stimulates B-lymphocyte proliferation in the mouse. Agents Actions. 6:1976;479-482.
39. Foekens J., Sieuwerts A., Stuurman-Smeets E., Dorssers L., Berns E., Klijn J. Pleiotropic actions of suramin on the proliferation of human breast cancer cells in vitro. Int. J. Cancer. 51(3):1992;439-444.
40. Rubio G., Pinedo H., Virizuela J., van Ark Otte J., Giaccone G. Effects of suramin on human lung cancer cell lines. Eur. J. Cancer. 31A:1995;244-251.
41. Andreotti P., Lee J.-M., Greenspan E., Bruckner H. Interaction of low-dose suramin with taxol. Proc. ASCO. 13:1994;165.
42. Lopez Lopez R., Van Rijswijk R., Wagstaff J., Pinedo H., Peters G. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumor effects of suramin. Eur. J. Cancer. 30A:1994;1545-1549.